Published in Medical Letter on the CDC and FDA, October 17th, 2004
An "intent to use" application for Oracea was filed on July 14, 2004 with the U.S. Patent and Trademark Office and the U.S. Food and Drug Administration (FDA).
"Oracea is a compelling brand name for our drug, which is currently under development to be the first FDA-approved oral treatment for rosacea," said Colin Stewart, president and chief executive officer of CollaGenex.
"We expect our two phase III...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA